Illexcor Holdings

Illexcor Holdings, LLC

1 Investors

Biopharmaceuticals

HENRICO, PA

Illexcor Therapeutics, LLC is a biopharmaceutical company dedicated to innovating treatments for sickle cell disease (SCD). Founded in 2020, the company has a mission to address the urgent unmet medical needs by developing oral therapies that effectively manage SCD on a global level.

Products & Team

ILX002

Oral therapySeed

ILX002 is Illexcor Therapeutics' lead drug candidate designed as a first-in-class oral medication that directly combats the causes of sickle cell disease. It operates by binding to hemoglobin S, effectively preventing the polymerization that leads to the sickling of red blood cells, even under low oxygen conditions.

Value Proposition

ILX002 aims to solve the critical challenge of managing sickle cell disease by offering a more effective and convenient oral therapy, which could transform SCD from a severe condition into a manageable chronic illness.

Pain Points

Patients currently face challenges with existing treatment options, including the invasiveness of bone marrow transplants and the complexity of gene therapies, which ILX002 aims to address by providing a more accessible oral treatment.

Targets hemoglobin S to prevent polymerizationInhibits sickling of red blood cellsProven efficacy in preclinical studies